News Feature

Filter By:

Article Type
  • Next-generation immuno-oncology targets continue to catalyze major deals, exemplified by the race to develop inhibitors of the immune checkpoint TIGIT.

    • Raveena Bhambra
    News Feature
  • After an unusual year, M&A activity picked up again in the biopharma industry with a number of billion-dollar deals.

    • Biopharma Dealmakers
    News Feature
  • COVID-19 has accelerated development and awareness of next-generation therapeutics, including mRNA vaccines, boosting the field’s dealmaking and investment activities.

    • Paul Verdin
    • Tsz Mon Tsang
    News Feature
  • This month we showcase the six-part Nature Careers podcast series, ‘Business of Science,’ which ran in May and June 2021 and aimed to teach new entrepreneurs about the first steps of research commercialization, from registering a patent, to scaling up and beyond.

    • Raveena Bhambra
    News Feature
  • Big pharma dealmaking returns to pre-pandemic levels as companies spend big to develop a range of cancer therapies.

    • Raveena Bhambra
    News Feature
  • Welcome to our May selection of key business of science stories from across Springer Nature’s portfolio of journals. This month we explore some stories based around COVID vaccines and bring to you the first two series of a Nature Careers ‘Business of Science’ podcast that aims to teach new entrepreneurs the first steps of research commercialization and patenting.

    • Raveena Bhambra
    News Feature
  • Plentiful financing and multiple pharma partnerships illustrate the burgeoning interest in applying artificial intelligence tools to drug research and development.

    • Neil Savage
    News Feature
  • Approaches such as gene therapy and nucleic acid-based therapies are emerging in recent deals related to potential treatments for ophthalmic diseases.

    • Biopharma Dealmakers
    News Feature
  • Welcome to our latest round up of key business of science stories from across Springer Nature’s portfolio of journals. This month we look at how biotech funding flourished during the pandemic, and explore the latest information regarding both AstraZeneca’s and Johnson & Johnson’s vaccines in the rollout against COVID-19.

    • Raveena Bhambra
    News Feature
  • Our monthly roundup of 'business of science' stories from across Springer Nature’s portfolio of journals explores the relationships between academia, startups and big pharma, as well as following the progress of the COVID-19 vaccine rollout.

    • Raveena Bhambra
    News Feature
  • A surge of efforts focused on the drug target B cell maturation antigen could transform the treatment of multiple myeloma and help to establish the relative merits and optimization strategies for emerging treatment modalities with wider applications.

    • John Hodgson
    News Feature